1 Division of Biological Sciences, University of Montana, Missoula, MT 59812, USA
2 Department of Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA
3 Department of Chemistry, University of Montana, Missoula, MT 59812, USA
Correspondence
Mary Poss
mary.poss{at}umontana.edu
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() |
---|
![]() |
MAIN TEXT |
---|
![]() ![]() ![]() ![]() |
---|
Diversity in the HIV-1 glycoprotein, gp120, encoded by env can significantly impact viral fitness by altering cell tropism and neutralization sensitivity. Substitutions in clade B gp120 that affect receptor and co-receptor binding and antibody interactions have been determined by mutagenesis studies (Boussard et al., 2002; Kwong et al., 2002
; Pantophlet et al., 2003
; Saphire et al., 2001
; Wyatt et al., 1998
; Zwick et al., 2003
). However, it is not known whether any key functional sites change as the virus establishes infection in a new host. Furthermore, despite the large number of clade A HIV-1-infected individuals worldwide, there has been no research on the structural biology of gp120 of non-clade B viruses. To gain a better understanding of forces acting on gp120 of a colonizing virus population, we developed a homology model of clade A HIV-1 gp120 to locate substitutions that arose between pre- and post-seroconversion samples in each of three clade A-infected women for whom extensive analysis of HIV-1 diversity (Poss et al., 1995
), plasma viral load and post-seroconversion env evolution (Poss et al., 1998
), and viral phenotype (Painter et al., 2003
) have been described.
To determine if there was measurable evolution near the time of infection, we recovered full-length env sequences from pre-seroconversion plasma viral RNA samples from each individual and from samples obtained at 20 (Q23), 7 (Q45) or 10 and 49 weeks (Q47) from the pre-seroconversion sample (Poss et al., 1995). The analysis employed a Markov Chain Monte Carlo (MCMC) framework and a general time reversible substitution model for the Bayesian estimation of evolutionary rates (Drummond et al., 2002
), incorporating a prior of time to most recent common ancestor estimated from a larger dataset of V12 and V3 sequences from these subjects (Poss et al., 1998
). The estimated evolutionary rate for Q23 sequences was 2·5 % per site per year (95 % confidence intervals 1·613·35) based on 16 plasma viral RNA sequences from two samples obtained 20 weeks apart. Rates of 0·28 % (0·070·51) were derived for Q45 based on 17 plasma viral sequences obtained 7 weeks apart. Viral RNA sequences were not available for Q47 at seroconversion and thus estimated rates of 0·13 % (0·050·22) were based on eight viral RNA pre-seroconversion sequences, seven proviral DNA sequences obtained 10 weeks later at the time seroconversion was detected, and 10 proviral sequences obtained 7 months after seroconversion. In all cases, confidence intervals excluded zero indicating that measurable rates of evolution occurred in env. There was no correlation between plasma viral loads and evolutionary rates in these individuals.
Protein sequences from pre-seroconversion samples were compared to those obtained at or near seroconversion to determine if amino acid replacement occurred in the evolving virus population. Although intra-sample sequence diversity was high (Fig. 1), in all three subjects amino acids at several positions in sequences derived at or shortly after seroconversion were replaced when compared with the sequences detected at the time of infection (Table 1
). Six substitutions were fixed in the seroconversion virus population of Q23. Four of these sites have been shown by mutagenesis studies of clade B gp120 to affect the binding of CD4 and one to affect binding of antibodies to the CD4-binding site (CD4BS) (Table 1
). Using a null distribution of 66 positions in gp120 affecting CD4 binding (Kwong et al., 1998
; Pantophlet et al., 2003
; Rizzuto et al., 1998
), there was a significantly higher number of substitutions at sites affecting binding to the CD4-binding site than would be expected if substitutions were randomly distributed (Fisher's exact test, P=0·009). Substitution T430A is of particular interest because alanine mutagenesis of this site in clade B gp120 strongly increased binding of antibody IgG1b12 (b12) (Pantophlet et al., 2003
; Saphire et al., 2001
) but decreased binding of CD4 (Rizzuto et al., 1998
), suggesting that this substitution could affect the structure of the receptor-binding domain. Three out of five temporal substitutions from Q45 viruses involved sites that affected CD4 and b12 or CCR5 binding to clade B gp120, which is significantly more than would be expected by chance (P=0·037). Temporal changes in Q47 sequences did not involve sites that have been investigated for impact on receptor, co-receptor or antibody binding, although sites 278 and 364 are adjacent to residues that contact CD4 (Kwong et al., 1998
). None of the temporal substitutions in either Q23 or Q45 sequences affected potential N-linked glycosylation sites or involved V1, V2 or V3, and none occurred in the gp41 portion of the glycoprotein (data not shown). In contrast, temporal substitutions in Q47 sequences did involve one site in V1 and gp41 (data not shown) and did result in two new potential N-linked glycosylation sites (Table 1
).
|
|
Despite the high prevalence of non-clade B HIV-1 infection globally, most structural, evolutionary and therapeutic research on HIV-1 is based on clade B viruses. Thus, it is not clear whether results obtained from clade B gp120 mutagenesis studies are applicable to clade A gp120. A crystal structure for clade B gp120 is available (Kwong et al., 1998, 2000a
) and provides the opportunity to determine the structural relatedness of gp120 from clades A and B. Using the clade B structure, we first identified substitutions specific to clade A gp120 from an alignment of consensus sequences of clade B and clade A (available at http://hiv-web.lanl.gov/), which are shown in red in Fig. 2
(A, B). Although clade A-specific substitutions are distributed throughout the sequence, there is a preponderance of differences in the silent face of the gp120 outer domain in
sheet 12 and 13 and
helix 2, which flank the V3 loop (Fig. 2A
). This
helix is known to be variable both within and between clades, which can lead to presentation of distinct antigenic surfaces to the immune system (Kwong et al., 2000a
). In the 3-D structure, substitutions characteristic of clade A occur at periodic intervals in the
helix and in a continuous stretch of the apposing
12 sheet to form a clade A-specific planar surface. In addition, there are several clade A changes within the CD4-binding pocket (Fig. 2B
). Clade A HIV-1 gp120s, including all representatives discussed herein, contain a substitution at P369, which is flanked by conserved CD4 contact residues D368 and E370. Substitutions of P369 decrease the binding of CD4 binding site antibody, b12 (Saphire et al., 2001
), and are a feature of clade B neutralization escape mutants (Mo et al., 1997
). Clade A-specific substitutions are also present in the bridging sheet, which is involved in co-receptor binding (Kwong et al., 1998
). It is noteworthy that there are few clade differences in the inner domain of gp120, a region of contact with gp41 (Kwong et al., 1998
).
|
The sequence with the longest V4 region, Q47S6 (AY288084), was threaded against the Q23Sc4 homology structure to display the temporal substitution. Virus populations from each of the three individuals evolved a temporal substitution in the inner domain near the truncated N terminus of gp120 (Fig. 2C), a region that is proximal to the viral membrane and that also accommodated clade A-specific changes (Fig. 2A
). The remainder of the inner domain did not change in the period following infection. Both Q45 and Q47 viruses had amino acid substitutions in V4 and the V4 stem, a region on the outer domain of the protein that does not contribute to virus neutralization. In both the Q23 and Q45 virus populations, temporal substitutions involved the bridging sheet and the V5 region (Fig. 2D
), which forms an upper surface to the CD4-binding pocket and has been implicated by mutagenesis to affect gp120receptor interaction (Table 1
). One of the Q47 substitutions (H364P) also lies on the lateral surface of the binding pocket and is adjacent to key CD4 contact residues (Kwong et al., 1998
).
Our data demonstrate that in three independent infections there is measurable evolution in HIV-1 env preceding and following seroconversion. We provide the first model of clade A gp120 and demonstrate that it has significant structural similarity with the clade B glycoprotein and that substitutions arising as the virus population becomes established in three hosts are not randomly distributed in the protein. Furthermore, in two of the three subjects there were significantly more changes at sites shown by mutagenesis of clade B gp120 to affect receptor or co-receptor binding than would be expected by chance. Further studies of the substitutions that arise soon after infection, will be valuable to understand selective forces acting on the infecting virus population and to inform efforts aimed at preventing establishment of new infections.
![]() |
ACKNOWLEDGEMENTS |
---|
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() |
---|
Drummond, A. J., Nicholls, G. K., Rodrigo, A. G. & Solomon, W. (2002). Estimating mutation parameters, population history and genealogy simultaneously from temporally spaced sequence data. Genetics 161, 13071320.
Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J. & Hendrickson, W. A. (1998). Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648659.[CrossRef][Medline]
Kwong, P. D., Wyatt, R., Majeed, S., Robinson, J., Sweet, R. W., Sodroski, J. & Hendrickson, W. A. (2000a). Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure Fold Des 8, 13291339.[Medline]
Kwong, P. D., Wyatt, R., Sattentau, Q. J., Sodroski, J. & Hendrickson, W. A. (2000b). Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol 74, 19611972.
Kwong, P. D., Doyle, M. L., Casper, D. J. & 18 other authors (2002). HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678682.[CrossRef][Medline]
Learn, G. H., Muthui, D., Brodie, S. J., Zhu, T., Diem, K., Mullins, J. I. & Corey, L. (2002). Virus population homogenization following acute human immunodeficiency virus type 1 infection. J Virol 76, 1195311959.
Long, E. M., Martin, H. L., Jr, Kreiss, J. K., Rainwater, S. M., Lavreys, L., Jackson, D. J., Rakwar, J., Mandaliya, K. & Overbaugh, J. (2000). Gender differences in HIV-1 diversity at time of infection. Nat Med 6, 7175.[CrossRef][Medline]
Lovell, S. C., Word, J. M., Richardson, J. S. & Richardson, D. C. (2000). The penultimate rotamer library. Proteins 40, 389408.[CrossRef][Medline]
Mo, H., Stamatatos, L., Ip, J. E., Barbas, C. F., Parren, P. W., Burton, D. R., Moore, J. P. & Ho, D. D. (1997). Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. J Virol 71, 68696874.[Abstract]
Painter, S. L., Biek, R., Holley, D. C. & Poss, M. (2003). Envelope variants from women recently infected with clade A human immunodeficiency virus type 1 confer distinct phenotypes that are discerned by competition and neutralization experiments. J Virol 77, 84488461.
Pantophlet, R., Ollmann Saphire, E., Poignard, P., Parren, P. W., Wilson, I. A. & Burton, D. R. (2003). Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol 77, 642658.[CrossRef][Medline]
Poss, M., Martin, H. L., Kreiss, J. K., Granville, L., Chohan, B., Nyange, P., Mandaliya, K. & Overbaugh, J. (1995). Diversity in virus populations from genital secretions and peripheral blood in women recently infected with human immunodeficiency virus type 1. J Virol 69, 81188122.[Abstract]
Poss, M., Gosink, J., Thomas, E., Kreiss, J. K., Ndinya-Achola, J., Mandaliya, K., Bwayo, J. & Overbaugh, J. (1997). Phylogenetic evaluation of Kenyan HIV-1 isolates. AIDS Res Hum Retroviruses 13, 493499.[Medline]
Poss, M., Rodrigo, A. G., Gosink, J. J., Learn, G. H., de Vange Panteleeff, D. D., Martin, H. L., Jr, Bwayo, J., Kreiss, J. K. & Overbaugh, J. (1998). Evolution of envelope sequences from the genital tract and peripheral blood of women infected with clade A human immunodeficiency virus type 1. J Virol 72, 82408251.
Rizzuto, C. D., Wyatt, R., Hernandez-Ramos, N., Sun, Y., Kwong, P. D., Hendrickson, W. A. & Sodroski, J. (1998). A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280, 19491953.
Saphire, E. O., Parren, P. W., Pantophlet, R. & 7 other authors (2001). Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293, 11551159.
Scarlatti, G., Tresoldi, E., Bjorndal, A. & 9 other authors (1997). In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 3, 12591265.[Medline]
Speck, R. F., Wehrly, K., Platt, E. J., Atchison, R. E., Charo, I. F., Kabat, D., Chesebro, B. & Goldsmith, M. A. (1997). Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol 71, 71367139.[Abstract]
Vranken, W. F., Fant, F., Budesinsky, M. & Borremans, F. A. (2001). Conformational model for the consensus V3 loop of the envelope protein gp120 of HIV-1 in a 20 % trifluoroethanol/water solution. Eur J Biochem 268, 26202628.
Wolfs, T. F., Zwart, G., Bakker, M. & Goudsmit, J. (1992). HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology 189, 103110.[Medline]
Wyatt, R., Kwong, P. D., Desjardins, E., Sweet, R. W., Robinson, J., Hendrickson, W. A. & Sodroski, J. G. (1998). The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393, 705711.[CrossRef][Medline]
Zhang, L. Q., MacKenzie, P., Cleland, A., Holmes, E. C., Brown, A. J. & Simmonds, P. (1993). Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol 67, 33453356.[Abstract]
Zhu, T., Mo, H., Wang, N., Nam, D. S., Cao, Y., Koup, R. A. & Ho, D. D. (1993). Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261, 11791181.[Medline]
Zwick, M. B., Kelleher, R., Jensen, R., Labrijn, A. F., Wang, M., Quinnan, G. V., Jr, Parren, P. W. & Burton, D. R. (2003). A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12. J Virol 77, 69656978.
Received 13 January 2004;
accepted 23 February 2004.
HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
J MED MICROBIOL | ALL SGM JOURNALS |